O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36

Nonalcoholic fatty liver disease (NAFLD) and its progressive variant, nonalcoholic steatohepatitis (NASH), constitute a burgeoning worldwide epidemic with no FDA-approved pharmacotherapies. The multifunctional immunometabolic receptor, fatty acid translocase CD36 (CD36), plays an important role in the progression of hepatic steatosis. O-GlcNAcylation is a crucial posttranslational modification that mediates the distribution and function of CD36, but its involvement in NAFLD remains poorly understood.

https://www.metabolismjournal.com/article/S0026-0495(24)00140-9/fulltext?rss=yes

Source: Metabolism - Clinical and Experimental - April 18, 2024 Category: Biomedical Science Authors: Hanlong Zhu, Tianming Zhao, Si Zhao, Suzhen Yang, Kang Jiang, Shupei Li, Ying Kang, Zhuoxin Yang, Jiajia Shen, Si Shen, Hui Tao, Ji Xuan, Miaofang Yang, Bing Xu, Fangyu Wang, Mingzuo Jiang Source Type: research